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Objectives: Cholinesterase inhibitors (ChEIs) offer modest beneﬁts in Alzheimer disease (AD), which must
be balanced against risks. Relatively few data delineate the beneﬁts and risks of long-term ChEI
administration in institutionalized patients with advanced AD. This study investigated the effects of ChEI
discontinuation in institutionalized patients with AD.
Design: Institutionalized patients with moderate to severe AD (standardized Mini- Mental Status Ex-
amination 15) and treated with a ChEI for 2 years were randomized, double-blind, to ChEI continu-
ation or placebo, with a 2-week tapering phase, for 8-weeks.
Measurements: The primary outcome of this pilot study was change on the Clinician’s Global Impression
of Change (CGI-C) scale. Secondary outcomes included safety, efﬁcacy, and tolerability. Baseline (BL)
predictors of clinical deterioration were also determined.
Results: Forty patients (mean  standard deviation age ¼ 89.3  3.5 years, standardized Mini-Mental
Status Examination ¼ 8.1  5.2, Neuropsychiatric InventoryeNursing Home version total
score ¼ 21.1  15.9, 80% male) were randomized to ChEI continuation (n ¼ 21) or placebo (n ¼ 19). There
was no signiﬁcant difference in clinical worsening in the ChEI continuation (28.6%) and placebo groups
(36.8%) on CGI-C (odds ratio for worsening 1.58, 95% conﬁdence interval .38e6.55, P ¼ .53). The occur-
rence of adverse events was similar in both groups. There were no signiﬁcant differences in any of the
secondary outcome measures. In the placebo group, BL hallucinations predicted CGI-C worsening
[F(1,17) ¼ 6.4, P ¼ .02], and there was a trend for BL delusions to predict CGI-C worsening [F(1,15) ¼ 3.5,
P ¼ .08].
Conclusions: These results suggest that ChEI discontinuation is safe and well tolerated in the majority of
institutionalized patients with moderate to severe AD. When discontinuing ChEI, the presence of hal-
lucinations and delusions may predict clinical deterioration, suggesting the need for increased caution.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).of Canada (#:12-74) and the
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and Long-Term Care Medicine. ThAlzheimer disease (AD) is the most prevalent form of dementia,
occurring in 5%e7% of individuals aged 60 and over.1 Patients with
moderate to severe AD account for an estimated 50% of all AD cases,
and it has been projected that in the future, those with moderate to
severe AD will represent 90% of patients residing in long-term care
(LTC).2,3
Currently approved treatments available for the symptomatic
management of mild tomoderate AD include cholinesterase inhibitors
(ChEIs); donepezil, rivastigmine, and galantamine, and the N-methyl-is is an open access article under the CC BY-NC-ND license (http://creativecommons.
N. Herrmann et al. / JAMDA 17 (2016) 142e147 143D-aspartate receptor antagonist, memantine. Donepezil, the riva-
stigmine transdermal patch, and memantine are also approved for the
treatment of severe AD.
Several clinical practice guidelines have proposed ChEIs for the
treatment of all stages of AD, with some advocating ChEI discontin-
uation if tolerability issues arise, or if there is no longer a noticeable
clinical beneﬁt.46 While ChEIs have demonstrated short-term stabi-
lization on measures of cognition and global functioning in random-
ized controlled trials (RCTs) of community-dwelling patients with
severe AD,7e10 data with respect to ChEI use in institutionalized pa-
tients with AD are limited. Further studies in this setting are important
because patients residing in LTC settings have increased AD severity,11
are more functionally impaired,12 present with more comorbid ill-
nesses,13 take more concomitant medications,14,15 and are on ChEIs for
a longer duration.16 In addition, ChEIs, although generally well toler-
ated, have potential adverse events (AEs) including nausea, diarrhea,
insomnia, vomiting, muscle cramping, fatigue, andweight loss.17e19 As
such, ChEI discontinuation in institutionalized patients with AD no
longer displaying obvious clinical beneﬁt may reduce the risk of AEs,
minimize polypharmacy, and reduce cost of care.
Currently, there are no double-blind RCTs addressing ChEI
discontinuation in moderate to severe institutionalized patients with
AD. The lack of data surrounding long-term ChEI use, coupledwith the
potential for AEs, make investigation of the effects of ChEI discon-
tinuation in this population warranted.
Methods
Study Participants
All patients were institutionalized and resided in 1 of 2 LTC facil-
ities. Informed consent was obtained from the patient’s substitute
decision maker and approved by the primary care physician. The
Research Ethics Boards at both sites approved this study.
Eligible patients were 55 years, met the National Institute of
Neurologic and Communicative Disorders and Stroke and the AD and
Related Disorders Association criteria for probable AD, met Diagnostic
and Statistical Manual of Mental Disorders-fourth edition criteria for
primary degenerative dementia, had a score of 15 on the Stan-
dardized Mini-Mental State Examination (sMMSE), and had been
treated with donepezil, galantamine, or rivastigmine (oral) for
2 years, with a stable dose for 3 months prior to study entry. Pa-
tients receiving a concomitant psychotropic had to be on a stable dose
for 1 month prior to study entry.
Patients were excluded if they had dementia unrelated to AD, were
treated with transdermal rivastigmine, had any uncontrolled medical
illness that would interfere with their participation in the study, or
had signiﬁcant difﬁculty ingesting oral medication.
Study Procedures
This was an 8-week randomized, double-blind, placebo-controlled
pilot trial. Following study entry, patients were randomized with a 1:1
balanced by ChEI to continue receiving their ChEI (continuation) at
their current dose, or to receive an identical-looking placebo substi-
tution. Patients randomized to placebo were tapered off their ChEI for
the ﬁrst 2 weeks and continued on placebo for the remaining 6 weeks.
Randomization was completed independently by the pharmacy at
Sunnybrook Health Sciences Center in permuted blocks using a
computer-generated code. Patients, family members, nurses, clini-
cians, outcome assessors, and investigators were unaware of treat-
ment group assignments or block size.
Following screening, patients were assessed at, 0 [baseline (BL)], 2,
4, and 8 (study endpoint) weeks. The study physician completed theClinician’s Global Impression (CGI) at 0, 4, and 8 weeks, and Clinician’s
Global Impression of Change (CGI-C) at 4 and 8 weeks. At 0, 4, and
8 weeks, patients completed 2 cognitive assessments, the sMMSE and
Severe Impairment Battery. Primary nurses completed the Udvalg for
Kliniske Undersogelser side effect rating scale, Neuropsychiatric
Inventory-Nursing Home edition (NPI-NH), Cornell Depression Scale
for Dementia, Apathy Evaluation Scale (AES), Cohen-Mansﬁeld
Agitation Inventory (CMAI), Alzheimer’s disease Cooperative Study-
Activities of Daily Living, modiﬁed for severe AD (ADCS-ADL-sev),
and Quality of Life in Late Stage Dementia (QUALID). At 2 weeks, pa-
tients completed the sMMSE, and primary nursing staff completed the
Udvalg for Kliniske Undersogelser side effect rating scale. Vital signs
(blood pressure, pulse rate, and weight) were obtained at each study
visit to monitor safety. Provided there was no substantial cognitive
deterioration (sMMSE total decrease 3 points compared with BL)20
or clinically signiﬁcant increase in neuropsychiatric symptoms (NPS)
(NPI-NH total increase 50% compared with BL),21 the randomized
treatment was continued.
Outcome Measures
The primary efﬁcacy outcome was CGI-C.22 The CGI-C is a 7-point
Likert scale (ranging from “marked improvement” to “marked wors-
ening”) that requires an experienced clinician to assess the degree to
which a patient’s illness has improved or worsened relative to a BL
state. The CGI-C requires the clinician to consider changes in the
cognitive, behavioral. and/or functional status of the patient. Given the
nature of this population’s signiﬁcant cognitive and functional
impairment necessitating full time institutional care, a global measure
of clinical status was considered the most ecologically valid primary
outcome measure, and the measure most clinicians and families
would rely on when considering drug discontinuation.23
The secondary outcome measures were safety, efﬁcacy, and toler-
ability. The safety outcome was determined by the number of indi-
vidual and total AEs experienced. All emergent AEs were noted and
followed up with until resolution. The efﬁcacy and tolerability of ChEI
discontinuation was determined by cognitive, functional, and behav-
ioral outcomes. Cognitive outcomes were determined by total scores
on the sMMSE and Severe Impairment Battery; the lower the score on
either assessment, the greater the cognitive impairment. The behav-
ioural outcomes were assessed by the NPI-NH (total score), CMAI, and
AES; the greater the score on the NPI-NH, CMAI, and AES, the greater
the overall behavioral disturbance, agitation, and apathy, respectively.
The functional outcome was determined by the ADCS-ADL-sev; the
lower the ADCS-ADL-sev score, the greater the functional impairment.
Quality of life was measured by the QUALID; the lower the QUALID
score, the lower the quality of life.
Sample Size
A sample size calculation was performed for the primary efﬁcacy
outcome described previously using a 2-tailed, 2-sample test of pro-
portions estimation method. The proportion of ChEI continuation
patients expected to deteriorate was based on Winblad et al,24 which
found that 18% of ChEI-treated patients showed clinically signiﬁcant
global deterioration (5, 6, or 7 on the CGI-C) over a similar time frame.
A sample size of 20 patients per group would be sufﬁcient to detect a
3.5-fold increase over the ChEI continuation group with 80% power
and a 5% signiﬁcance level as well as allow for 1 covariate.
Statistical Analysis
To compare BL characteristics between the treatment groups, in-
dependent t-tests (for parametric data) and Mann-Whitney U tests
N. Herrmann et al. / JAMDA 17 (2016) 142e147144(for nonparametric data) were computed for each medical, cognitive,
behavioral, and functional measure.
The primary assessment of efﬁcacy was based on an intention-to-
treat comparison of the CGI-C ratings at week 8. The CGI-C ratings
were grouped into clinical improvement/no change and clinical
worsening. A logistic regression analysis, adjusting for BL sMMSE, was
used to compare CGI-C ratings between the treatment groups. An
observed case analysis with study completers and a subanalysis
comparing antipsychotic users with nonusers was also completed.
To assess the safety of ChEI discontinuation, a c2 or Fisher exact
test was used to determine the association between treatment group
and AE occurrence and to determine if the proportion of participants
with AEs was greater in those with CGI-C worsening at 8 weeks. To
determine the efﬁcacy and tolerability of ChEI discontinuation on
cognition, behavior, function, and caregiver distress, a repeated
measures analysis of covariance was used to compare groups over
time (0, 4, and 8 weeks) for each cognitive, behavioral, and functional
measure, and caregiver distress score on the NPI-NH, controlling for
treatment group and BL sMMSE scores.274 ChEI Users in Long-te
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Fig. 1. ParticipantA linear regression model was runwithin each group to determine
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Study Patient Characteristics
Forty institutionalized patients with moderate to severe AD were
randomized to ChEI continuation (N ¼ 21) or placebo (N ¼ 19), and all
were included in the analyses (Figure 1). All BL characteristics were
comparable, except patients randomized to ChEI continuation had
lower sMMSE scores (Table 1). Of the 40 randomized, 33 patients
(82.5%) completed the study (85.7% continuation, N ¼ 18; 78.9%
placebo, N ¼ 15;); 1 died prior to study completion (unrelated to
study) (placebo), 1 was terminated early because of a serious AE
(continuation), 1 was lost to follow-up (continuation), 1 had clinically
signiﬁcant cognitive decline (placebo), and 3 had clinically signiﬁcant
behavioral deterioration (2 placebo, 1 continuation). Number of early
terminations [c2(1) ¼ .316, P ¼ .57], time to early termination, asrm Care
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Table 1
Baseline Characteristics
Demographics/
Baseline
characteristics
Total
(N ¼ 40)
Placebo
(ChEI Disc.)
(N ¼ 19)
ChEI Cont.
(N ¼ 21)
P Value
Age (years) 89.2 ( 3.5) 89.7 ( 3.8) 88.9 ( 3.3) .46
Sex (%M) 80 73.7 85.7 .34
Number of
concomitant
illnesses
6.4 ( 2.43) 6.5 ( 2.8) 6.29 ( 2.1) .62
Number of
concomitant
meds
12.3 ( 5.5) 11.3 ( 5.2) 13.2 ( 5.7) .23
ChEIs
Donepezil 17 7 10 .49
Galantamine 16 8 8 .80
Rivastigmine 7 4 3 .57
Psychotropics
Memantine 37.5 31.6 42.9 .46
Antidepressants 45 42.1 47.6 .73
Antipsychotics 32.5 26.3 38.1 .39
Baseline Parameters
CGI 3.7 ( 0.7) 3.5 ( 0.7) 3.8 ( 0.6) .20
Weight (kg) 71.1 ( 14.5) 67.1 ( 14.9) 74.9 ( 13.4) .15
sMMSE 8.1 ( 5.2) 10.0 ( 5.1) 6.4 ( 4.8) .03
SIB Total 56.9 ( 31.1) 63.7 ( 28.0) 50.8 ( 33.1) .20
NPI-NH Total 21.1 ( 15.9) 20.3 ( 18.0) 21.9 ( 14.0) .52
Delusions (NPI-NH) 1.15 ( 2.95) 1.95 ( 4.02) .43 ( 1.12) .13
Hallucinations
(NPI-NH)
.37 ( 1.35) .47 ( 1.43) .29 ( 1.31) .67
NPI-NH disruption
total
7.9 ( 6.4) 7.8 ( 7.3) 8.0 ( 5.7) .94
CMAI 46.9 ( 13.7) 44.1 ( 12.4) 49.6 ( 14.6) .26
AES 55.9 ( 11.2) 52.4 ( 12.7) 59.0 ( 8.7) .08
ADCS-ADL-sev 12.7 ( 10.0) 14.2 ( 10.9) 11.3 ( 9.1) .50
QUALID 21.6 ( 7.2) 20.1 ( 6.6) 23.0 ( 7.7) .15
ChEI, cholinesterase inhibitor; Disc, discontinuation; Cont, continuation; sMMSE,
Standardized Mini Mental State Examination; SIB, Severe Impairment Battery; CGI,
Clinician’s Global Impression Scale; NPI-NH, Neuropsychiatric Inventory - Nursing
Home version; CMAI, Cohen-Mansﬁeld Agitation Inventory; AES, Apathy Evaluation
Scale; ADCD-ADL-sev, Alzheimer’s Disease Co-operative Study - Activities of Daily
Living Inventory, modiﬁed for severe AD; QUALID, Quality of Life in Late-Stage
Dementia scale.
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[t(5) ¼ .48, P ¼ .65] and percent drug compliance (97.3% placebo;
96.6% continuation, U ¼ 162, P = .30) did not signiﬁcantly differ
between groups.Table 2
Frequency of AEs
AE Placebo
(N ¼ 19)
ChEI Continuation
(N ¼ 21)
Total
(N ¼ 40)
Unintentional weight loss (<1.66%) 5 3 8
Fall 3 3 6
Loss of consciousness 0 1 1
Vomiting 0 2 2
Perineum wound 0 1 1
Oral thrush 1 0 1
IV due to poor appetite 1 0 1
Respiratory tract infection 1 1 2
Conjunctivitis 0 1 1
Dizziness 0 1 1
Rash 0 1 1
Cognitive decline/confusion 1 0 1
Acute/unproductive cough 0 1 1
Deterioration in behavior 3 2 5
Bradycardia 0 1 1
Serious AEs 1 2 3
Bowel obstruction 1 0 1
Seizure 0 1 1
Atrial ﬁbrillation 0 1 1Study Outcomes
Minimal to marked worsening over 8 weeks on the CGI-C occurred
in 6 continuation (28.6%) vs 7 placebo-treated (36.8%) participants.
When adjusting for BL sMMSE, treatment group was a nonsigniﬁcant
predictor of CGI-C worsening at 8 weeks [odds ratio (OR) for wors-
ening 1.58, 95% conﬁdence interval (CI) .38e6.55, P ¼ .53]. In a post-
hoc analysis adjusting for BL sMMSE and for antipsychotic use, to
account for frequent antipsychotic use in this study population,
treatment group remained a nonsigniﬁcant predictor of CGI-C wors-
ening (OR for worsening 1.67, 95% CI .40e7.10, P¼ .49). In a subanalysis
of study completers (n¼ 33), when adjusting for BL sMMSE, treatment
group was a nonsigniﬁcant predictor of CGI-C worsening (OR for
worsening 1.95, 95% CI .31e12.17, P ¼ .48).
The frequency of AEs is presented in Table 2. Unintentional weight
loss (20% of total) and falls (15% of total) were the most common AEs
experienced by study participants. However, treatment allocation did
not have a signiﬁcant effect on AE occurrence [c2(1) ¼ 2.41, P ¼ .12],
clinically signiﬁcant weight loss (P ¼ .44, Fisher exact test), or the
occurrence of falls (P ¼ 1.0, Fisher exact test). In addition, AE occur-
rence did not have a signiﬁcant effect on CGI-Cworsening in thewhole
group (P ¼ .50, Fisher exact test), the continuation group (P ¼ .12,
Fisher exact test), or the placebo group (P ¼ 1.0, Fisher exact test).
Mean change scores on all BL parameters are shown in Table 3.
When controlling for BL sMMSE scores and treatment group, there
was no signiﬁcant effect of time on any cognitive, behavioral, and
functional measures, or caregiver distress score on the NPI-NH.
In the placebo group, hallucinations at BL (NPI-NH) signiﬁcantly
predicted CGI-C worsening at study endpoint [F (1,17) ¼ 6.39, P ¼ .02]
while delusions at BL (NPI-NH) approached signiﬁcance
[F(1,15) ¼ 3.45, P ¼ .08]. Hallucinations and delusions accounted for
27.3% and 13.3% of the explained variance in CGI-C worsening,
respectively. In the placebo group, 31.6% of the patients who experi-
enced delusions and/or hallucinations at BL, also experiencedminimal
to marked worsening (Figure 2).
Discussion
This study suggests that ChEI discontinuation is safe and well
tolerated in institutionalized patients with moderate to severe AD
who have been treated for at least 2 years. ChEI discontinuation was
not associated with CGI-C worsening, increased AE occurrence, clini-
cally signiﬁcant weight change, falls, or changes in caregiver distress.
However, the presence of hallucinations and delusions in the placebo
group at BL suggested that those NPS may predict clinical deteriora-
tion when discontinued from ChEI treatment.
Currently, ChEIs are recommended for the treatment of moderate
to severe AD, however, the American Geriatrics Society Choosing
Wisely Workgroup suggests that clinicians should consider discon-
tinuation if the cognitive, behavioral, and functional goals of the
patient’s treatment plan are not met.25 A meta-analysis of 5 ChEI
discontinuation, double-blind RCTs reported that ChEI discontinua-
tion increases the rate of cognitive and behavioral deterioration.26
However, of those studies, only the Donepezil and Memantine for
Moderate to Severe Alzheimer Disease trial speciﬁcally included pa-
tients with moderate to severe AD, and that study excluded institu-
tionalized patients. The Donepezil and Memantine for Moderate to
Severe Alzheimer Disease trial demonstrated that ChEI discontinua-
tion may lead to cognitive and functional deterioration, while having
no signiﬁcant effect on NPS.7 Though the results of our study also
indicated that treatment allocation did not have a signiﬁcant effect on
NPS, it did not replicate the ﬁndings of the other studies, as we found
that treatment allocation did not have a signiﬁcant effect on the
change of cognition, function, or global ratings over 8 weeks. In
addition to differences in setting, those studies involved participants
Table 3
Change Scores (Baseline to 8 Weeks)
Parameter Placebo Cholinesterase Cont. P Value
BL (Mean  SD) Endpoint (Mean  SD) Change (Mean  SD) BL (Mean  SD) Endpoint (Mean  SD) Change (Mean  SD)
CGI 3.5  0.7 3.6  0.4 0.1  0.5 3.8  0.6 3.8  0.8 0.0  0.4 .64
CGI-C* n/a n/a 3.6  1.1* n/a n/a 3.4  1.2* .55
Weight (kg) 67.1  14.9 66.9  15.2 0.4  2.2 74.8  13.4 74.4  12.5 0.4  4.1 .84
sMMSE 10  5.1 8.8  5.6 1.0  4.0 6.4  4.8 7.1  5.8 0.7  3.1 .19
SIB 63.7  28.0 57.2  34.7 6.5  21.3 50.8  3.1 49.5  35 1.3  14.6 .25
NPI-NH 20.3  18 23.8  3.6 3.6  12.6 21.9  14 20.9  18.4 1.1  8.9 .24
NPI-disruption 7.8  7.3 8.8  9.8 1.0  4.2 8.0  5.7 7.8  7.0 0.2  6.3 .28
CMAI 44.1  12.4 43.8  9.1 0.3  7.3 49.6  4.6 52.3  19.3 2.5  11.2 .90
AES 52.4  12.7 54.2  12.5 1.8  7.6 59  8.7 62.3  5.9 3.3  5.5 .32
ADCS-ADL-sev 14.2  10.9 14.1  11.1 0.1  3.8 11.3  9.1 11.3  9.1 0.0  3.4 .54
QUALID 20.1  6.6 20.4  7.2 0.3  3.1 23.0  7.7 22.9  8.5 0.1  4.8 .92
ANCOVA, analysis of covariance; cont, continuation; n/a, not applicable (change score only); sMMSE, Standardized Mini-Mental State Examination; SD, standard deviation;
SIB, Severe Impairment Battery.
Asterisk (*) denotes that the reported CGI-C score is reported as the score provided by the study physician at study endpoint. This score represents how the patient has
improved or worsened clinically, from baseline. Because this score was taken from a single point in time, a Mann-Whitney U test was used to compute the P value. For all other
measures, a repeated measures ANCOVA, controlling for BL MMSE scores, was used to compute the P values.
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sMMSE scores.26 As such, these differences suggest that previous
ﬁndings may not apply to institutionalized, more elderly populations,
who often reach the stage where discontinuation of medications may
be considered.
ChEI treatment has been associated with an increased risk of
nausea, vomiting, weight loss, syncope, and bradycardia.1719 Those
AEs must be taken into consideration during ChEI discontinuation as
the patient group is both frail and elderly, and there may not be suf-
ﬁcient beneﬁt from the treatment to justify such AEs. Furthermore,
polypharmacy is a worrisome issue because swallowing medications,
and the occurrence of drug-related AEs are common in institutional-
ized patients with advanced dementia.27,28 Though the results of our
study suggest that there was no signiﬁcant effect of treatment allo-
cation on early terminations or AE occurrence, 60% of participants
(N ¼ 24) experienced 1 or more AEs during the study. There was no
signiﬁcant association between AE occurrence and clinical deteriora-
tion (CGI-C) within the study group, and within each treatment allo-
cation.While this study suggests that ChEIs can be safely discontinued
inmany institutionalized, patients withmoderate to severe treated for
2 years, of particular clinical relevance was the ﬁnding that BL scores
of psychosis (hallucinations and delusions) correlated with worsening
following discontinuation. We, therefore, suggest clinicians closely
monitor patients with psychotic symptoms if discontinuation is
attempted.
It is interesting to speculate on why NPS like hallucinations and
delusions were associated with clinical worsening following ChEI
discontinuation. Studies have shown that cholinergic deﬁciency may
contribute to the development of NPS in moderate to severe AD, and
that these NPS may improve after ChEI use, and worsen with anti-
cholinergic medications.29 Three RCTs of patients with AD reported
NPS worsening in those randomized to placebo when compared with0
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Fig. 2. Proportion of ChEI discontinued patients with and without delusions and
hallucinations (NPI-NH).ChEI treatment.3032 An open label study with donepezil in 120
patients with AD, with amean NPI total score of 30 at BL, reported that
after 20 weeks of ChEI use, there was a30% reduction in the NPI total
score in 62% of patients, with a 27% reduction in delusions, halluci-
nations, and sleep domains from BL.33 In a post hoc analysis of 2033
patients with AD (double blind RCT with galantamine), in 57% of pa-
tients treated with galantamine, there was 30% reduction in the
hallucination and delusions NPI score, with 72% of patients treated
with galantamine having a 30% reduction in hallucinations.34 It is,
thus, possible to explain the worsening of hallucinations and de-
lusions through discontinued ChEI use, its consequent increase in
cholinergic deﬁciency,35 and its subsequent contribution to clinical
deterioration in the study group.
Study strengths included randomization, double-blinding, use of
placebo control using an identical appearing capsule, and careful
assessment of AEs, cognition, function, and behavior using scales
appropriate to the population and setting. Nevertheless, there are
certain limitations that should be taken into consideration. Patients
from the Sunnybrook Veterans’ Center are predominantly male,
introducing sampling bias, because males are overrepresented at this
site. Observational36 and retrospective37 studies suggest that being
male is signiﬁcantly associated with psychosis in AD. Although
another cross-sectional study did not replicate those ﬁndings, they did
ﬁnd that male sex was signiﬁcantly associated with agitation at the
moderate and severe stages of AD.38 This study also allowed
concomitant use of antipsychotics as antipsychotics are commonly
used in long-term care in patients with moderate to severe AD and
behavioral disturbances. Even though this could mask medication
effects, there were no signiﬁcant differences between treatment
groups in the number of individuals taking psychotropics. In addition,
when controlling for antipsychotic use, treatment group was not a
signiﬁcant predictor of clinical deterioration (CGI-C). It should also be
noted that patients on the rivastigmine patch were excluded. This
exclusion criterion was necessary as study participants were required
to take study medication in capsule form, but limits generalizability to
that group. Similarly, patients who were not medically stable, or were
in palliative care were excluded. As a result, patients included in the
study may have been healthier and have had a better response to
pharmacologic intervention. This study may also be considered to
have a short duration of follow-up. However, we have demonstrated
in a meta-analysis of previous ChEI discontinuation RCTs that most of
the deterioration occurs within the ﬁrst 6 weeks of discontinuation.26
Finally, this study also had a small sample size, which should be
considered when interpreting results. Though not statistically signif-
icant, clinical deterioration in the placebo group was numerically
N. Herrmann et al. / JAMDA 17 (2016) 142e147 147greater than that in the ChEI continuation group. A post hoc analysis of
the mean of change scores between the treatment groups indicated
that in order to obtain results with an analytical power of 80%, the
sample size required is 520 participants for the CGI-C. Although sta-
tistically signiﬁcant differences might have been detected with this
large sample size, differences may not have been clinically relevant
when balanced against risks in this population. At the very least, the
results of this study provide necessary pilot data on the safety and
tolerability of ChEI discontinuation, as well as some potential in-
dicators of clinical factors that make discontinuation riskier.
Conclusions
This study of the safety and tolerability of ChEI discontinuation in
institutionalized patients with moderate to severe AD provides the
ﬁrst evidence in this setting and adds to the limited evidence in those
with advanced AD. These results contrast with previous studies in
community-dwelling participants, which found continued efﬁ-
cacy.7,30,32 This discrepancy calls for future ChEI discontinuation trials
in institutionalized patients with more advanced AD. Further study
may provide insight into those who should, and should not continue
ChEI treatment, and may support a broader literature dealing with
discontinuing medications of questionable beneﬁt in the frail and
elderly.
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